重组人白介素11治疗前期再生障碍性贫血的血小板减少的初步观察  

Clinical Efficacy of Recombinant Human Interleukin 11 on Thrombocytopenia in Pre-Aplastic Anemia

作　　者：商安芳[1] 郭静明[1] 商建东 刘小慧[1] 艾红[1] 朱磊[1] 曾一琴[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院血液科 [2]重庆市大足县人民医院,重庆402360

出　　处：《中国实验血液学杂志》2005年第1期151-153,共3页Journal of Experimental Hematology

摘　　要：为了评价重组人白介素 11治疗前期再生障碍性贫血的血小板减少的疗效 ,对 6例早期再生障碍性贫血患者用重组人白介素 116 0 0万单位皮下注射 ,每日 1次 ,疗程 7- 14天 ,并分别于治疗前、治疗后第 8天、第 15天、第 30天、第 6 0天复查外周血血小板 ,第 15天复查骨髓巨核细胞计数。结果表明 :显效 3例 (5 0 % ) ,良效 1例(16 .7% ) ,进步 1例 (16 .7% ) ,无效 1例 (16 .7% ) ,总有效率 83.3%。全部 6例病人骨髓巨核细胞均有不同程度增加 ,治疗时副作用轻。结论 :重组人白介素 11治疗前期再生障碍性贫血血小板减少的疗效满意。To evaluate the clinical efficacy of recombinant human Interleukin 11 in the treatment of pre-aplastic anemia, six patients with pre-aplastic anemia were injected with rhIL-11 of 6 million units once a day during 7-14 days. Blood platelet counts were taken on day 8, 15, 30 and 60 after the treatment, and bone marrow examination was performed on day 15 as compared with those before treetment. The results showed that platelet counts in 3 out of 6 patients increased remarkably (50%), one of the six increased moderately (16.7%), another case of the six increased slightly (16.7%), platelet in one out of six did not significantly increase (16.7%), the total efficacy rate is 83.3%, the amount of megakaryocyte in bone marrow of all six patients increased, the side effect of the rhIL-11 treatment was light. In conclusion, the efficacy of recombinant human Interleukin-11 in the treatment of thrombocytopenia patients with pre-aplastic anemia is satistactory. As the number of the cases is too small to conclude, further exploration needs accumnlation of more applications.

关 键 词：重组人白介素11 再生障碍性贫血 血小板 

分 类 号：R556.5[医药卫生—血液循环系统疾病] R558.2[医药卫生—内科学]